GlassScriptPhysician profile
Kellie Vaughn
NPI 1245705698
$11,642.57
in general payments reported to CMS, 2019-2025
22 companies · $1,825 in 2025
The $1,825 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,725 · 2022: $3,284 · 2023: $1,814 · 2024: $995 · 2025: $1,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,633.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,803.52 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,366.59 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $741.87 | 2021-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $593.23 | 2021-2025 | Trintellix |
| Alkermes, INC. | $591.37 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $363.57 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Janssen Pharmaceuticals, INC | $362.66 | 2021-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $352.79 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $281.06 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $201.06 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $188.65 | 2022-2025 | Fanapt |
| Corium, LLC | $172.91 | 2021-2023 | Azstarys |
| Lundbeck LLC | $141.11 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $112.82 | 2025 | Cobenfy |
| Tris Pharma INC | $90.24 | 2021-2024 | Dyanavel Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $90.13 | 2021 | |
| Ironshore Pharmaceuticals INC. | $60.51 | 2022 | |
| Almatica Pharma LLC | $41.49 | 2023 | Loreev Xr, Sertraline Hcl |
| Adlon Therapeutics L.P. | $30.10 | 2021 | |
| Neos Therapeutics, LP | $21.54 | 2022 | |
| Noven Therapeutics, LLC | $19.45 | 2024 | Xelstrym, Secuado |
| Eisai INC. | $15.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Vaughn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.